Overview

A Study to Test GlaxoSmithKline's (GSK) Respiratory Syncytial Virus RSV Candidate Vaccine's Safety and Immune Response in Japanese Older Adults

Status:
Completed

Trial end date:
2020-12-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of 2 doses of GSK Biologicals' RSV candidate vaccine adjuvanted with AS01B for the prevention of lower respiratory tract diseases caused by RSV in ethnic Japanese adults 60-80 years of age.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Vaccines